A New Therapeutic Strategy for Type 2 Diabetes - Free CE ...

More documents

Recommendations

Info

Overview• Underlying defects with Type 2 diabetes• Importance of managing postprandialglucose control• Incretin Hormones– New therapies that target incretin hormones©MedOutcomes, Inc. 2008
The Diabetes Epidemic• 8.0% of US childrenand adults havediabetes.• 57 million have prediabetes• 1.6 million new casesdiagnosed in peopleaged 20 years or olderin 2007.• 90-95% Type 2©MedOutcomes, Inc. 20085.7millionundiagnosed17.9milliondiagnosedNational Diabetes Statistics Fact Sheet. 2008.JAMA 2007;297:2716-2724.
Page 1: Modulating the Incretin System:A Ne
Page 5 and 6: Normal Glucose HomeostasisGlucagon(
Page 7 and 8: Natural History of Type 2 DiabetesP
Page 9 and 10: Other fundamental defects inType 2
Page 11: Unmet Pathophysiologic Needs in Typ
Page 14 and 15: Recent Trials in Type 2 DM• ACCOR
Page 16 and 17: Mean Plasma GlucoseA1C (%) Mean pla
Page 18 and 19: GOOD GLYCEMIC CONTROL: ACRITICAL BU
Page 20 and 21: Patients With Type 2 Diabetes May S
Page 22 and 23: Incretin Hormones• Peptides produ
Page 24 and 25: GLP-1 Actions in HumansUpon ingesti
Page 26 and 27: Incretin-Based Therapies• Increti
Page 28 and 29: Exenatide (Byetta ® )What to Do Ab
Page 31 and 32: Improvement in HOMA-BFrom Baseline
Page 33: Sitagliptin (Januvia ® )• Orally
Page 36 and 37: ©MedOutcomes, Inc. 2008• Adverse
Page 38 and 39: Vildagliptin (Galvus ® )• Indica
Page 40 and 41: GLP-1 Mimetics versus DPP-IVInhibit
Page 42 and 43: Who might benefit most fromincretin
Page 44: To Sum It All Up• Incretin hormon

A New Therapeutic Strategy for Type 2 Diabetes - Free CE ...

Create successful ePaper yourself

Delete template?

Save as template?